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underlying mechanisms for diastolic dysfunction in patients with mitral and aortic valve disease. In addition to load,
intrinsic myocardial abnormalities occur related to changes in sarcomeric proteins, abnormal calcium handling, and
ﬁbrosis. Echocardiography is the initial modality for the diagnosis of left ventricular diastolic function. Although there
are challenges to conventional Doppler parameters of diastolic function, it is often possible to arrive at a clinically
useful assessment of left ventricular ﬁlling pressures using a comprehensive approach. When needed, cardiac
magnetic resonance and cardiac catheterization can be obtained. Medical therapy can be of value for the treatment
of diastolic dysfunction, but there is a paucity of data evaluating its clinical utility. More importantly, diastolic
dysfunction usually improves with timely surgical intervention, although surgery does not always lead to
normalization of function. (J Am Coll Cardiol 2013;62:1922–30) ª 2013 by the American College of Cardiology
FoundationThe diagnosis of diastolic heart failure is entertained in
the absence of hemodynamically signiﬁcant valvular heart
disease. However, patients with valvular heart disease fre-
quently have symptoms of pulmonary and/or systemic
congestion due to increased left ventricular (LV) ﬁlling
pressures and/or diastolic dysfunction. In this review, we
discuss the mechanisms behind pre-operative and post-
operative diastolic dysfunction in patients with aortic and
mitral valve disease, the diagnostic aspects of diastolic
dysfunction in these patients, and the implications for
treatment.Aortic Stenosis
Aortic stenosis (AS) is the most common reason for
valve replacement in the United States. Calciﬁc AS is
present in 2% to 4% of the population over age 65 years
and in as many as 8% of the elderly population by age
85 years (1).
Mechanisms of diastolic dysfunction in AS. Patients with
moderate to severe AS usually have concentric LV hyper-
trophy, which is associated with myocardial dysfunction due
to abnormal calcium handling, disruption of cellularist DeBakey Heart and Vascular Center, Methodist Hospital,
he authors have reported they have no relationships relevant to the
per to disclose.
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0, 2013.organization, loss of contractile elements, apoptosis, vascular
rarefaction, titin isoenzyme shifts, and ﬁbrosis. The LV
hypertrophy allows for a lower end-systolic wall stress, and
normal ejection fraction (EF), albeit systolic abnormalities
can be detected by myocardial strain (2). At this stage,
diastolic dysfunction is quite common and is related to
impaired and delayed relaxation and increased LV chamber
stiffness.
Increased chamber stiffness is in turn related to increased
LV mass/end-diastolic volume (EDV) ratio and increased
myocardial stiffness. For myocardial stiffness, increased in-
terstitial ﬁbrosis is an important contributing factor (3,4).
Other mechanisms include decreased titin N2BA/N2B iso-
form ratio and its hypophosphorylation (5,6). Both changes
result in a higher tension for a given sarcomere length. Se-
condary pulmonary hypertension is one of the consequences
of diastolic dysfunction, and the link between them can be
evaluated by noninvasive studies at rest and during exercise
(7,8). Secondary mitral regurgitation (MR) can occur with
LV systolic dysfunction and annular dilation, and when
MR is hemodynamically signiﬁcant, it can contribute to
elevated left atrial (LA) pressure and pulmonary artery
(PA) pressures. Finally, subendocardial ischemia can occur
because of lower coronary perfusion and exacerbates myo-
cardial abnormalities.
Diagnosis of diastolic dysfunction. ECHOCARDIOGRAPHY.
The American Society of Echocardiography/European
Association of Echocardiography diastolic function
guidelines can be applied to AS patients on the basis
of LV EF and taking into consideration the limitations of
Abbreviations
and Acronyms
AR = aortic regurgitation
Ar = atrial reversal velocity
AS = aortic stenosis
AVR = aortic valve
replacement
CMR = cardiac magnetic
resonance
DT = deceleration time
EDP = end-diastolic pressure
EDV = end-diastolic volume
EF = ejection fraction
IVRT = isovolumic relaxation
time
LA = left atrial
LV = left ventricular
MR = mitral regurgitation
MS = mitral stenosis
PA = pulmonary artery
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1923the different indices (Table 1). Impaired myocardial
relaxation can be inferred in the presence of reduced e’
velocity as well myocardial diastolic strain rate. In the
presence of normal or reduced LVEDV along withDoppler
ﬁndings of increasedﬁlling pressures, one can conclude thatLV
chamber stiffness is increased. Doppler predictors of elevated
LV end-diastolic pressure (EDP) are particularly useful in
identifying myocardial abnormalities independent of MR and
LA dysfunction. These include mitral A-wave duration and its
deceleration time (DT [both shortened]), pulmonary vein atrial
reversal velocity (Ar) and duration (both increased), and
mitral annulus a’ velocity (decreased). Clinical management
can be inﬂuenced by knowing the status of LV ﬁlling pres-
sures as this would conﬁrm or refute the presence of a cardiac
etiology for dyspnea in patients with coexisting pulmonary
disorders. With depressed EF, mitral inﬂow parameters can
be applied for assessment of LV ﬁlling pressures (9). When
LVEF is>50%, mitral E/e’ ratio is the starting point (9). Of
note, some elderly patients with AS have severe mitral
annular calciﬁcation, which is a limitation to the application
of E/e’ ratio (Fig. 1).
Stress echocardiography using a supine bike protocol can
provide useful data on LV systolic reserve (changes in stroke
volume, EF, and global longitudinal strain) and diastolic
reserve (changes in e’ velocity, E/e’ ratio, and PA pressures).
It is often difﬁcult to distinguish the effects of the valve
lesion itself, systolic dysfunction, and diastolic dysfunction
on abnormal resting or exercise echocardiographic and
hemodynamic recordings. Notwithstanding, recent studies
support the clinical promise of using exercise PA pressure
estimation for the management of patients with asymp-
tomatic severe AS (8).
CARDIAC MAGNETIC RESONANCE. In patients with subop-
timal echocardiographic images, cardiac magnetic resonance
(CMR) can provide an accurate assessment of LV and aortic
valve morphology and function. In addition, CMR can be
used to quantify the presence and extent of replacement
ﬁbrosis due to myocyte loss as well as interstitial ﬁbrosis
(10,11). Fibrosis measurements are of interest because theyTable 1
Summary of Applications and Limitations
Valvular Heart Disease
Doppler Parameter Values Indicating Increased LV F
Mitral E/A ratio* >1.2 with depressed EF
DT of mitral E <160 ms with depressed EF
Pulmonary vein S/D* <1 with depressed EF
Peak Ar velocity*y >30 cm/s
Ar  A duration*y 35 ms
E/e’ ratio Septal >15, lateral >12, avg >13
IVRT/ TE-e’z <3 for MR, <4.2 for MS
PA systolic pressure >35 mm Hg
*Parameter cannot be obtained with atrial ﬁbrillation. ySignal detects increase
ﬁbrillation, it can still be applied if matched RR intervals are available.
Ar ¼ aortic reversal velocity; AR ¼ aortic regurgitation; Avg ¼ average of sep
IVRT ¼ isovolumic relaxation time; LA ¼ left atrial; MAC ¼mitral annular calciﬁ
artery; S/D ¼ systolic/diastolic; TE-e’ ¼ time between onset of mitral E velocitcan help explain the mechanisms
behind diastolic dysfunction as
well as predict outcome after
surgery (3,4).
CARDIACCATHETERIZATION. Aside
from the assessment of aortic valve
hemodynamics, it is possible to
measureLVdiastolic pressures, PA
pressures, and the time constant of
LV relaxation (Tau) using high-
ﬁdelity pressure transducers. LV
volumes, operating chamber stiff-
ness, and modulus of chamber
stiffness (k) can be obtained using
conductance catheters.
Diastolic dysfunction and clin-
ical outcomes before and after
aortic valve replacement. There
are few studies that evaluated the
relation between diastolic dys-
function and clinical outcomes in
AS. In a recent study of 125 AS
patients who have not undergone valve surgery, E/e’ ratio
was the most predictive parameter of clinical events among
clinical and imaging measurements (12). Likewise, LV
diastolic dysfunction (inferred using E/e’ ratio) was an
important independent predictor of early, midterm, and late
mortality after aortic valve replacement (AVR) (13,14).
LV diastolic dysfunction after AVR in patients with AS.
After surgery, LV ﬁlling usually improves, with an increase in
LV EDV and regression of LV hypertrophy. Early
improvement in LV ﬁlling appears related to the decrease in
LV mass/EDV ratio (15,16). Likewise, an increase in coro-
nary ﬂow reserve can be seen early on concomitant with the
decrease in LV EDP (17).
Notwithstanding the above observations, there are care-
fully performed clinical studies that have shown an increase
in LV chamber stiffness early after AVR. This was associ-
ated with an increase in interstitial ﬁbrosis and occurredof Doppler Parameters in Patients With
illing Pressures Limitations
Severe AR and MR with normal EF
Severe AR
Severe MR
Suboptimal signals, LA dysfunction
Suboptimal signals, LA dysfunction
Severe MR or MS, severe MAC
Challenging in atrial ﬁbrillation
Coexisting pulmonary disease
d left ventricular (LV) end-diastolic pressure. zWhile challenging in atrial
tal and lateral E/e’ ratios; DT ¼ deceleration time; EF ¼ ejection fraction;
cation; MR ¼mitral regurgitation; MS ¼mitral stenosis; PA ¼ pulmonary
y and annular e’ velocity.
Figure 1 Doppler Signals From a Patient With AS and Severe Mitral Annulus Calciﬁcation
Pulmonary venous ﬂow (upper left), mitral inﬂow (upper right), tricuspid regurgitation (TR) jet by continuous wave (CW) Doppler (lower left), and mitral annulus velocities at
lateral annulus (lower right) from a patient with severe mitral annular calciﬁcation and severe aortic stenosis (AS). Mitral peak E velocity is increased and lateral annular e’
velocity is decreased because of heavy annular calciﬁcation, and thus E/e’ erroneously suggests increased left ventricular (LV) ﬁlling pressures. Pulmonary veins systolic/
diastolic ratio, pulmonary veins atrial reversal velocity (Ar) minus mitral A-wave velocity duration, and pulmonary artery systolic pressure (estimated at 29 mm Hg assuming right
atrial pressure of 5 mm Hg; inferior vena cava diameter <2 cm with spontaneous collapse) are all indicative of normal LV ﬁlling pressures. This patient had LV diastolic pressure
before left atrial contraction of 8 mm Hg and LV end-diastolic pressure of 9 mm Hg by left heart catheterization. a’ ¼ late diastolic velocity; S’ ¼ systolic velocity; TD ¼ tissue
Doppler.
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1924despite a reduction in LV mass. Late after surgery, myo-
cardial stiffness constant decreases in parallel with the
decrease in myocyte diameter and ﬁbrosis (18).
Patient-prosthesis mismatch can contribute to persistent
diastolic dysfunction due to elevated LV systolic pressure
and limited regression of LV hypertrophy. It appears that
diastolic dysfunction is one of the major mechanisms by
which mismatch contributes to clinical events of death and
hospitalizations in this setting (19).
Diagnosis of LV diastolic dysfunction after AVR. The
diagnostic evaluation of these patients is geared toward
identifying and grading the diastolic dysfunction as well as
determining the potential underlying reasons. The latter
include LV systolic dysfunction, post-operative valve prob-
lems including patient-prosthesis mismatch, and pericardial
diseases. Doppler methodology as described earlier can
be applied to provide important insights explaining the
persistent symptoms of pulmonary congestion (Fig. 2).
Implications for treatment before and after AVR. Aside
from the temporary use of diuretics, AVR (surgery or per-
cutaneous) is the treatment for diastolic dysfunction in AS
patients. Several reports have shown that AVR leads to animprovement in LV ﬁlling pressures (20). Post-operatively,
adequate control of hypertension and the careful use of di-
uretic therapy can help achieve better symptomatic control
in patients with pulmonary congestion. In that regard, the
use of selective antihypertensive therapy may have unique
advantages of improving diastolic dysfunction and clinical
outcomes.
Angiotensin-receptor blockers have been examined as
potential therapy after AVR because of their ability to
accelerate LV mass regression and thus improve diastolic
function. Candesartan was administered after AVR in 114
patients, who were randomly assigned to the drug at 32 mg
per day or to conventional treatment. Although there were
no signiﬁcant differences between the 2 groups in blood
pressure, candesartan was effective in accelerating LV and
LA remodeling at 12 months, compared to conventional
treatment, but had no effects on E/e’ ratio and B-type
natriuretic peptide levels (21). In another randomized study
with 91 patients, the administration of the drug at 32 mg per
day was associated with a signiﬁcantly lower incidence of
post-operative new-onset atrial ﬁbrillation at 3 to 12 months
after AVR (22). This is likely related to the improvement in
Figure 2 Doppler Signals From a Patient With Persistent Dyspnea After AVR
Doppler data from a patient with prosthetic aortic valve (AV) who presented with persistent dyspnea 8 months after aortic valve replacement (AVR). The left ventricle (LV) was
normal in size with ejection fraction at 58%. Continuous wave (CW) Doppler of the AV is shown (upper left) with normal peak velocity and mean gradient of 12 mm Hg consistent
with normal prosthetic valve function. Mitral inﬂow at tips level is shown (upper right) with restrictive LV ﬁlling (peak E velocity at 115 cm/s). There is an L-wave (arrow), which is
consistent with impaired LV relaxation and increased LV ﬁlling pressures. Peak velocity of tricuspid regurgitation (TR) jet (3.5 m/s) corresponds to a pulmonary artery systolic
pressure of at least 48 mm Hg (lower left). Septal annular velocities are shown (lower right); septal E/e’ ratio is 38.3, consistent with markedly elevated LV ﬁlling pressures
(>25 mm Hg). TD ¼ tissue Doppler.
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1925LV ﬁlling and the decrease in LA volumes as a consequence
of accelerated LV mass regression. The use of these drugs
was further explored in patients with prosthesis mismatch in
a randomized trial that included 72 patients in which a dual
renin-angiotensin inhibition regimen was associated with
a larger decrement in LV mass and a lower incidence of
residual LV hypertrophy (23). In comparison with these
studies, there is no evidence that statin therapy alters valvular
or ventricular function after AVR.
Aortic Regurgitation
Mechanisms of diastolic dysfunction. In patients with
chronic aortic regurgitation (AR), the left ventricle
undergoes remodeling such that its dimensions/volumes and
mass increase with eccentric hypertrophy. In the compen-
sated state, the LV is more compliant and accommodates
the increased LV EDV with normal diastolic pressures.
Later on, LV stiffness and ﬁlling pressures increase marking
the presence of the decompensated state. This stage can be
accompanied by symptoms and signs related to the increase
in LV ﬁlling pressures and pulmonary congestion.
Diastolic dysfunction in chronic AR occurs because of
impaired LV relaxation and increased myocardial stiffness
(24). Myocardial samples from chronic AR patients exhibitincreased cell diameter and ﬁbrous content (25). In 1 study,
c-Myc protein expression was related to pathological
changes (26), whereas in another study, upregulation of the
ﬁbronectin gene along with increased ﬁbronectin deposition
were implicated (27).
Diagnosis of diastolic dysfunction. In the presence with
severe AR and normal LV diastolic function, mitral inﬂow is
characterized by predominant early ﬁlling and the annular e’
velocity is normal or increased due to increased LV stroke
volume. Accordingly, E/e’ ratio is usually not increased,
and PA pressures are normal (Fig. 3). With LV diastolic
dysfunction, LV ﬁlling pressures and PA pressures are
elevated at ﬁrst with exercise, and later on, at rest. Of note,
severe AR in and of itself can inﬂuence Doppler parameters
if the AR jet contributes to the rapid rise in LV diastolic
pressures (9). This can be manifested by a short DT of
mitral E velocity (Table 1).
Diastolic dysfunction and clinical outcomes after AVR.
There is a paucity of data on the relationship between LV
diastolic function and clinical events in patients with
chronic AR undergoing AVR. In 1 study of 41 patients
with chronic severe AR and LV systolic dysfunction, LV
diastolic function was useful in predicting outcome after
AVR (28). The EF increased in patients with grade I
Figure 3 Doppler Findings From a Patient With Severe AR
Color Doppler of the atrial regurgitation (AR) jet in the parasternal long axis view (left), mitral inﬂow (middle), and lateral mitral annulus TD velocities (right). The patient has
severe chronic AR with a severely enlarged left ventricle. The AR regurgitant volume was 70 ml, with regurgitant fraction of 50%. Mitral peak E velocity and annular e’ velocity are
increased, with E/e’ ratio of 9.3. The AR jet (arrow) is impinging on mitral inﬂow and is precluding clear delineation of mitral A-wave velocity. TD ¼ tissue Doppler.
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1926diastolic dysfunction whereas it decreased in patients with
grade III dysfunction. On multivariable regression analysis,
DT was an independent predictor of changes in EF after
AVR.
Diastolic dysfunction after AVR. After AVR, LV volume
and mass decrease with improvement in LV ﬁlling, although
this can be delayed (15). In that regard, the type of the
prosthetic valve used can affect post-operative LV function
as stentless valvesdin comparison with stented valvesdare
usually associated with earlier and larger decrements in LV
dimensions and mass as well as better LV function (29).
Overall diastolic dysfunction appears to have a higher
prevalence and worse severity late after surgery after AVR
for AR as opposed to surgery for AS. In 1 study, LV
structure and function were evaluated serially in 11 patients
before AVR and 21 and 89 months after AVR. Post-
operatively, LV mass decreased but EF did not change.
LV relaxation was signiﬁcantly prolonged before surgery and
was normalized at 87 months after AVR. LV diastolic
stiffness constant was increased not only before surgery, but
also remained elevated early and late after AVR. That
occurred despite signiﬁcant decrease in muscle ﬁber diam-
eter, which nevertheless remained increased at late follow-
up. Interstitial ﬁbrosis likely played a major role in the
persistently elevated diastolic stiffness constant as it was
increased pre-operatively and increased even further early
after surgery, although it decreased late after AVR, albeit
still higher than that seen in control subjects. Importantly,
ﬁbrosis was positively correlated to myocardial stiffness (30).
Diagnosis of diastolic dysfunction after AVR. In the
presence of persistent ﬁndings of pulmonary or systemic
congestion, it is reasonable to obtain an echocardiogram
for the evaluation of LV diastolic function. The already
mentioned guidelines (9) can be applied in this setting. It is
important to look at potential contributing factors fordiastolic dysfunction such as patient-prosthesis mismatch,
and signiﬁcant residual AR.
Implications for treatment before and after AVR. AVR
can lead to an improvement in LV diastolic dysfunction, but
not necessarily normalization in patients with severe chronic
AR. Aside from surgery, there are few investigations that
explored the effects of medical therapy on LV diastolic
function. In 1 study, spironolactone was administered to
adult Wistar rats with severe AR for 6 months. Treatment led
to a decrease in cardiac mass, decreased expression of atrial
natriuretic peptide messenger ribonucleic acid, collagen I, and
LOX1 messenger ribonucleic acids, and total ﬁbrosis (31).
Given the detrimental effects of ﬁbrosis on LV diastolic
function, this drug can be of potential value, although this
awaits clinical studies.
Beta-blockers are another class of drugs that can improve
LV diastolic function. Data from an animal model of severe
AR showed favorable effects of carvedilol on LV remodeling
and ﬁlling pressures (32). This was accompanied by an
increase in b1-receptor expression and an improvement in
myocardial capillary density. In addition, there is an obser-
vational study showing survival advantage for AR patients
treated with beta-blockers (33).
The presence of diastolic dysfunction after AVR can be
treated with adequate control of hypertension and careful use
of diuretics. In particular, spironolactone and torasemide
may offer additional beneﬁts through their additional effects
on decreasing interstitial ﬁbrosis. Unlike for AS, there are no
studies that speciﬁcally examined medical treatment after
AVR for patients with severe AR.
Mitral Stenosis
Mechanisms of diastolic dysfunction. Patients with
mitral stenosis (MS) often have an elevated LA pressure at
rest and/or with exercise. That is primarily due to the
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1927stenotic mitral valve. The LV stroke volume is often
reduced with severe stenosis as a result of decreased LV
ﬁlling and EDV. In most patients, LV systolic and diastolic
functions are normal. However, there are reports of
abnormal LV function (34,35). In 1 study with conduc-
tance catheters, LV chamber stiffness was increased in
severe MS and improved acutely with valvuloplasty. The
exact mechanism behind the altered LV chamber stiffness
is not clear, although restriction of LV expansion by its
attachment to a thickened and immobile mitral valve has
been postulated (34). In addition, older patients with MS
can have myocardial abnormalities related to coronary
artery disease, AS, or hypertension.
Diagnosis of diastolic dysfunction. ECHOCARDIOGRAPHY.
There are challenges to the accuracy of Doppler indices of
MS in the setting of LV diastolic dysfunction. These
include a lower transmitral pressure gradient despite an
elevated LA pressure due to the concomitant increase in LV
diastolic pressures. Likewise, pressure half time of mitral E
velocity can be short due to the increase in LV chamber
stiffness leading to a faster rise in LV diastolic pressure
despite MS. Ultimately, the true severity of valvular stenosis
can be most reliably assessed in these patients by using
3-dimensional planimetery of the mitral valve area (Fig. 4,
Online Video 1).
Regarding the assessment of LV diastolic function in
patients with MS, conventional Doppler indices are not
reliable (Table 1). The E/e’ ratio is usually elevated, as
peak E velocity is increased and e’ velocity is reduced (36).
Nevertheless, it is still advantageous to estimate LA pressure
as it relates to MS severity. When LA pressure is increased,
LV isovolumic relaxation time (IVRT) is short (<70 ms),Figure 4 Echocardiographic Assessment of Mitral Stenosis in Patien
(A) Continuous wave (CW) Doppler of mitral inﬂow obtained by transesophageal echocardi
had hypertension and concentric left ventricular (LV) hypertrophy. Mitral valve area (MVA)
pressure half time is suggestive of moderate mitral stenosis. That was largely due to incre
3-dimensional echocardiography in the same patient. Valve area by 3-dimensional echoca
Online Video 1.and peak E velocity is increased in the range of 1.5 m/s to
2 m/s (9). Furthermore, patients with elevated LA pressure
often have an increased late diastolic A velocity >1.5 m/s
along with pulmonary hypertension. More recently, the time
interval delay between onset of mitral E velocity and annular
e’ velocity has been examined. With normal LV relaxation, e’
occurs at the same time as mitral E or precedes it.
Conversely, with impaired LV relaxation, onset of e’ is
delayed after onset of mitral E velocity (37,38). This time
interval when combined with IVRT as the ratio of IVRT/
TE-e’ has been shown to relate well to mean pulmonary
capillary wedge pressure and LA pressure in MS patients
(decreasing ratio as LA pressure increases) (36).
CARDIAC CATHETERIZATION. Cardiac catheterization di-
rectly assesses MS severity (transmitral pressure gradient
and mitral valve area) and its consequences of pulmonary
hypertension. With severe LV diastolic dysfunction, the
transmitral pressure gradient can underestimate MS severity
as LV diastolic pressures are elevated because of associated
cardiac disease. That is observed more frequently in older
patients with MS. In these patients, it is important to
measure not only the gradient but also isolated LA and LV
diastolic pressures, as both will be elevated. In comparison,
patients with MS and normal diastolic function usually
have low to normal LV diastolic pressures due to reduced
LV ﬁlling.
When both conditions of MS and diastolic dysfunction
coexist, it is possible to distinguish the contribution of
diastolic dysfunction to the elevated LA pressure by lo-
wering LV afterload using a vasodilator agent (such as
sodium nitroprusside). When LV diastolic dysfunction is the
main reason for dyspnea, the decrease in LV systolic andt With Coexisting Diastolic Dysfunction
ogram from a patient with New York Heart Association functional class IV. The patient
by pressure half time was 1.5 cm2 with a mean gradient of 9.5 mm Hg. The area by
ased LV stiffness leading to shorter pressure half time. (B) Mitral valve (MV) area by
rdiography was 0.7 cm2, consistent with severe mitral stenosis. See accompanying
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1928diastolic pressures with lower afterload can be accompanied
by a decrease in LA pressure (39). Conversely, with severe
MS and minor abnormalities of LV diastolic function, one
would expect only small decrease, if any, in LA pressure.
Finally, it is possible to measure the time constant of
LV pressure decay and LV chamber stiffness using con-
ductance catheters to document the presence and severity of
diastolic abnormalities, although this is not routinely
performed.
Implications for treatment. The presence of diastolic
dysfunction and its contribution to symptoms is important
to recognize as isolated treatment of MS may not result in
complete relief of symptoms, particularly in cases with severe
diastolic dysfunction. Furthermore, when MS plays only
a minor role in causing cardiac symptoms, invasive proce-
dures aimed at its treatment expose the patient to risks (such
as bleeding and perforation), while offering little, if any
beneﬁt. For these patients, good control of blood pressure
and adequate doses of diuretic therapy can result in symp-
tomatic improvement and lower PA pressures. In particular,
beta-blockers and rate-slowing calcium-channel blockers
can be helpful as they prolong the diastolic ﬁlling interval,
which is beneﬁcial for MS as well as LV diastolic dysfunc-
tion (although there are situations where the negative lusi-
tropic properties of these drugs can lead to slower LV
relaxation).
Effects of balloon valvuloplasty on LV diastolic function.
After percutaneous mitral valve commissurotomy, LV ﬁlling
improves with an increase in LV EDV, EF, stroke volume,
and a decrease in systemic vascular resistance. That is
accompanied by a small increase in LV EDP immediately
after the procedure, but with normalization of EDP at 12
months of follow-up (40). It is likely that the increase in LV
ﬁlling accounts for the early increase in LV EDP, but in
the absence of intrinsic myocardial disease, the procedure
in and of itself does not result in long-term changes in
LV diastolic pressures, although LA pressure decreases.
Mitral Regurgitation
Mechanisms of diastolic dysfunction. Isolated severe
chronic MR leads to LV and LA dilation in an attempt to
accommodate the MR volume without an increase in LV
and LA pressures. Accordingly, in patients with chronic MR
and normal LV function, LV chamber stiffness is usually
reduced (41). However with LV contractile dysfunction,
LV ﬁlling pressures and myocardial stiffness constant are
elevated. In addition, patients with MR can have LV dia-
stolic dysfunction due to coexisting hypertension, diabetes
mellitus, and coronary artery disease.
After surgical correction, LV volumes, early ﬁlling rate,
and compliance all decrease (42). Interestingly, in isolated
cardiomyocytes from animals with chronic severe MR, the
lengthening rate was reduced only in myocytes with reduced
shortening (43), and isolated problems with myocyte
lengthening have not been reported.Diagnosis of diastolic dysfunction. ECHOCARDIOGRAPHY.
There are challenges to the echocardiographic assessment
of diastolic function with severe MR. With severe MR and
normal EF, mitral peak E velocity is often increased (usually
>1.2 m/s) and E/A ratio is >1. That is due to severe MR
and not to diastolic dysfunction (9). Likewise, systolic
blunting can be observed in pulmonary venous ﬂow in the
absence of increased LA pressure (9). Likewise, e’ velocity is
increased and E/e’ ratio is not predictive of LV ﬁlling
pressures (9,36). Conversely, the Ar velocity in pulmonary
venous ﬂow can be helpful as it relates to LV late diastolic
pressures that are not affected by severe MR (36,44).
It is also possible to use the time interval between
onset of E velocity and onset of e’ velocity to assess LV
diastolic function in MR. Similar to MS, this time
interval is prolonged with impaired LV relaxation, and the
ratio of IVRT to TE-e’ can be used to predict LV ﬁlling
pressures, irrespective of LV systolic function and MR
severity (36).
CARDIAC CATHETERIZATION. Cardiac catheterization di-
rectly assesses the severity of MR and its consequences of
pulmonary hypertension. Importantly, one can measure LV
pre-A pressure and LV EDP. In patients with severe MR
and normal LV function, both pressures are normal.
Pulmonary hypertension when present is due to the increase
in mean LA pressure that occurs when LA stiffness is
increased. The increased LA stiffness can be manifested by
a prominent “v” wave signal in the LA pressure recording.
Although it is important to determine the contribution of
LV diastolic dysfunction to the symptomatic status in
hypertensive patients with signiﬁcant MR, that can be
challenging because a decrease in LA pressure with arterial
vasodilators can be due to lower LV diastolic pressures as
well as to a decrease in MR severity.
Diastolic dysfunction and prediction of outcome.
Diastolic function is an important determinant of exercise
tolerance in patients with MR. In 1 report, baseline LV
EDV, time to peak systolic mitral annular velocity, and E/e’
ratio were the determinants of exercise PA systolic pressure
in asymptomatic patients with at least moderateMR (45). In
another study, mitral e’ velocity and pulmonary venous Ar
velocity were the only parameters that determined exercise
duration in MR patients (46). Interestingly, rest and stress
PA systolic pressure, LV EF, and MR regurgitant fraction
showed no signiﬁcant correlation with exercise duration.
A recent study reported the impact of LV diastolic function
on outcome after restrictive mitral ring annuloplasty in
chronic ischemicMR. Early mortality rate was highest among
patients with restrictive LV ﬁlling. A DT <140 ms and
pulmonary vein systolic/diastolic velocity ratio<0.80were the
independent predictors of early and late mortality. Impor-
tantly, DT <140 ms was the only independent predictor of
MR recurrence (47).
MR treatment and LV diastolic function. Early surgery
preceding the development of the decompensated stage can
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1929prevent the occurrence of myocardial dysfunction in patients
with MR, and late surgery may have a minor impact on
myocardial abnormalities. More recently, there has been
growing interest in the treatment of patients with functional
MR. The surgical approach often includes the use of
restrictive annuloplasty. Invasive studies using pressure-
volume loops in patients with dilated cardiomyopathy and
functional MR have reported a modest decrease in LV
EDV and end-systolic volume, accompanied by a small
increment in LV EF (on average 4%, although statistically
signiﬁcant). Conversely, both tau and stiffness constant
increased signiﬁcantly, indicating deterioration in LV dia-
stolic function after surgery (48).
For percutaneous treatment for MR, there is a paucity of
data on the effects of the MitraClip procedure on LV func-
tion. In a recent study of 33 patients with functional and de-
generativeMR, the procedure was associated with an increase
in end-systolic wall stress and a decrease in end-diastolic wall
stress and mean wedge pressure, but without a signiﬁcant
change in LV end-systolic pressure volume relation (49).
Additional studies are needed with adequate numbers in the
different subsets as the effects of percutaneous repair on LV
function are likely variable based on MR etiology.
Diagnosis of diastolic dysfunction after surgery. The
diagnosis of diastolic dysfunction by echocardiography
after surgery can be challenging as many Doppler param-
eters are affected by the surgery itself. After implantation
of a surgical ring or a prosthetic valve, mitral E velocity
increases and e’ velocity decreases. Accordingly, E/e’ ratio
can be increased even though LA pressure may not be
elevated. Other signals should be evaluated in this setting,
including pulmonary veins, tricuspid regurgitation peak
velocity, and the ratio of IVRT to TE-e’. The latter ratio
was able to track changes in ﬁlling pressures after mitral
valve surgery with reasonable accuracy (36). Of note, it is
important to exclude other reasons (aside from diastolic
dysfunction) that can lead to increased LA pressure in the
post-operative setting, such as a restrictive annular ring
leading to MS, prosthetic valve dysfunction, and para-
valvular MR.
Treatment of diastolic dysfunction after surgery. Isolated
diastolic dysfunction in the post-operative setting does not
occur. However, it usually occurs with coexisting systolic
dysfunction. Accordingly, patients can be treated with
beta-blockers, angiotensin-converting enzyme inhibitors/
angiotensin-receptor blockers, and spironolactone with loop
diuretics as needed. Although it is not known whether
medical treatment in the pre-operative setting can affect post-
operative LV diastolic function, beta-blockers can be of
potential value; a recent randomized study in 38 asymptom-
atic patients with moderate to severe MR using metoprolol
for 2 years showed favorable effects not only on LV EF but
also on LV early diastolic ﬁlling rate as assessed by CMR. The
drug had no signiﬁcant effects on LV mass, wall thickness, or
longitudinal strain rate (50).Reprint requests and correspondence: Dr. Sherif F. Nagueh,
Department of Cardiology, Methodist DeBakey Heart and
Vascular Center, 6550 Fannin Street, SM-677, Houston,
Texas 77030. E-mail: snagueh@tmhs.org.REFERENCES
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